Why the study?
Patients at HBR continue to receive BMS due to fear of bleeding or stent thrombosis from premature DAPT discontinuation with DES, making the comparative efficacy and safety of DES versus BMS with short or tailored DAPT an open question.
Do drug-eluting stents reduce MACE compared to bare metal stents in high bleeding risk patients undergoing PCI with short or tailored DAPT?
Do drug-eluting stents reduce MACE compared to bare metal stents in high bleeding risk patients undergoing PCI with short or tailored DAPT?
In high bleeding risk patients undergoing PCI, drug-eluting stents with short or tailored DAPT reduce MACE compared to bare metal stents without increasing bleeding or stent thrombosis.
Answers are grounded in this paper and cite their sources.
DES with short/tailored DAPT was associated with lower MACE without excess bleeding or ST in HBR patients; leaves open randomized confirmation.
OBJECTIVES: To determine the efficacy and safety of drug-eluting stents (DESs) and bare metal stents (BMSs) when used with short or tailored dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients. BACKGROUND: DES have been shown to reduce target lesion revascularization (TLR) as well as stent thrombosis (ST) compared to BMS in patients undergoing percutaneous coronary intervention (PCI). However, patients at HBR continue to receive BMS given the fear of bleeding or ST from premature discontinuation of DAPT in patients receiving DES. METHODS: We performed a meta-analysis of randomized controlled trials by performing systematic search for studies comparing DES with BMS in HBR patients using PUBMED, MEDLINE, and Cochrane Central, reported until March 1, 2018. RESULTS: Three randomized controlled studies met the inclusion criteria with total of 4,460 patients; 50% received DES. Major adverse cardiovascular event (MACE); composite of death, myocardial infarction (MI), and TLR, at 1 year was significantly lower (RR = 0.63, 95% CI 0.50-0.80) in DES group compared to BMS. This difference was primarily driven by lower TLR (RR = 0.46, 95% CI 0.35-0.61) in DES group. Definite or probable ST (RR = 0.59, 95% CI = 0.32-1.08) and major (RR = 0.94, 95% CI = 0.74-1.20) bleeding were similar. CONCLUSIONS: DES was associated with lower MACE without increased risk of bleeding or ST compared to BMS when used with short or tailored DAPT in patients with HBR.
No takes yet. Share an insight, caveat, or question.
Neupane et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: